- Eli Lilly’s Weight Loss Drug, Tirzepatide, Shows Promising Phase 3 Results: If Approved, Next Hurdle Would Be Reimbursement Forbes
- Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 | Eli Lilly and Company Eli Lilly
- SURMOUNT-1: Adults achieve weight loss of 16% or more at 72 weeks with tirzepatide Healio
- Lilly’s experimental obesity drug may be a ‘multibillion-dollar opportunity’ MarketWatch
- Tirzepatide: Does this new weight loss drug really have the same results as surgery? The National
- View Full Coverage on Google News
Brought to you by Google News. Read the rest of the article here.